Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia This ad hoc analysis of data from 2 clinical trials examines factors that may predict complete response in patients with chronic lymphocytic leukemia or small lymphocytic leukemia treated with ibrutinib. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/jama/prognostic-factors-for-complete-response-to-ibrutinib-in-patients-with-70ineVgDpN

References (17)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2017.5604
Publisher site
See Article on Publisher Site

Abstract

This ad hoc analysis of data from 2 clinical trials examines factors that may predict complete response in patients with chronic lymphocytic leukemia or small lymphocytic leukemia treated with ibrutinib.

Journal

JAMA OncologyAmerican Medical Association

Published: May 22, 2018

There are no references for this article.